There are many decisions to be made in an adult life; among them are cancer prevention screenings. They are voluntary and many people deliberate whether they should go or not and if they would actually want to know the results. Apart from screening participants, science, politics and health care professionals also ponder with each new preventive service whether it is beneficial and who should end up paying for it.
A tumor is as unique as the person who is affected by it. For a long time, it was assumed this would make treatment more difficult since cancer drugs are not able to be one hundred percent effective in targeting the affected cells. In this interview with MEDICA.de, Professor Ugur Sahin explains why it is precisely these individual mutations that make him hopeful for a new type of therapy.
Can liquid biopsies become the new trend in cancer diagnostics? The medical world has asked this question for quite some time. The first globally approved liquid biopsy-based test for lung cancer shows that this can work. Yet further findings and research are still required to establish this less invasive method in diagnostics.